Monoclonal antibody significantly reduces nasal polyps and need for surgery in Phase 3 clinical trial
Chronic rhinosinusitis with nasal polyps presents a substantial clinical burden, affecting nasal airflow, olfactory function, ...
Medscape6d
Tezepelumab Eases Chronic Rhinosinusitis With Nasal Polyps
The asthma medication reduces congestion in patients with severe, uncontrolled chronic rhinosinusitis with nasal polyps in a ...
Taiwan News23h
Nasal Polyposis Treatment Market Valued at USD 4.6 Billion in 2023, Expected to Grow at 6.3% CAGR Through 2032
Read the Market Summary Here:- https://reportocean.com/industry-verticals/sample-request?report_id=bw8527 ...
Nasal Polyps Treatment Market Set To Surge To $4.24 Billion By 2030 At A 5.6% CAGR
Nasal Polyps Treatment Market Research Report The global nasal polyps treatment market is expected to reach around $4,243.9 million by 2030 ...
GSK's Twice-Yearly Depemokimab Reduces Nasal Polyp Size, Goes Under FDA Review
FDA reviews GSK depemokimab for asthma and CRSwNP, with a decision expected by December 2025. Phase 3 data shows improvements ...
Fierce Biotech13d
GSK gears up for depemokimab debut with twin FDA filings and phase 3 data dump
With Sunday’s Academy Awards ceremony in the rearview mirror, GSK is looking ahead to a potential blockbuster premiere of its ...
Lyra Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Company continues to focus on upcoming results from ENLIGHTEN 2 pivotal Phase 3 trial in CRS patients, expected in 2Q 2025In parallel, the ...
Pulmonology Advisor6d
Silent Rhinovirus Infection Prevalent in Nasal Tissues
Silent rhinovirus (RV) infection is prevalent in nasal tissues and is associated with distinct immune responses in those with and without chronic rhinosinusitis with nasal polyps (CRSwNP). These were ...
Fierce Pharma13d
Sinusitis data from Amgen, AZ's Tezspire spark 'best-in-disease' talk amid Sanofi, GSK competition
Already billed as a potential blockbuster, Amgen and AstraZeneca’s Tezspire has turned in strong clinical data in chronic ...